Advertisement
ABT vs MDT
Which Stock Would AI Choose? Abbott Laboratories (ABT) vs. Medtronic (MDT) Stock Comparison
Key Takeaways
- ABT and MDT are leading healthcare equipment companies with overlapping exposure to medical devices and diagnostics.
- ABT reported strong Q2 2026 results and raised full-year adjusted EPS guidance to $5.45–$5.60, supported by diagnostics and device growth.
- MDT delivered its highest annual revenue growth in a decade in fiscal 2026, with analysts raising price targets ahead of Q1 FY2027 earnings.
- ABT trades at a higher valuation (P/E ~36) than MDT (P/E ~24), reflecting differences in growth profiles and margins.
- Recent product milestones, including ABT’s FDA authorization for dual glucose-ketone monitoring and CE Mark for Amulet 360, contrast with MDT’s pipeline momentum in cardiovascular and diabetes segments.
- Both stocks have shown resilience in a volatile market, though relative performance has varied with sector sentiment and company-specific catalysts over recent weeks.
Introduction
Abbott Laboratories (ABT) and Medtronic (MDT) represent two prominent players in the healthcare equipment sector, offering diversified exposure to medical devices, diagnostics, and related therapies. Investors and traders comparing these names often seek to evaluate differences in growth trajectories, valuation, recent operational execution, and positioning within the broader medtech landscape. This analysis focuses on observable factors such as earnings performance, product developments, and market positioning over recent weeks to provide a balanced view relevant to those assessing relative opportunities in large-cap healthcare equities.
ABT Overview and Recent Performance
Abbott Laboratories develops and manufactures a range of healthcare products spanning medical devices, diagnostics, nutrition, and established pharmaceuticals. In recent market activity, the stock has traded near $112, with a market capitalization of approximately $194.6 billion. Following its Q2 2026 earnings release, the company raised its full-year adjusted EPS guidance to a range of $5.45 to $5.60, citing strength in diagnostics and medical devices segments. Key developments in recent weeks include FDA authorization for the world’s first dual glucose-ketone sensing technology and CE Mark approval for the next-generation Amulet 360 device targeting atrial fibrillation patients. These milestones have contributed to sentiment alongside a litigation settlement related to infant formula products. Performance has reflected broader healthcare sector dynamics, with modest fluctuations amid earnings momentum and product news.
MDT Overview and Recent Performance
Medtronic plc designs and manufactures medical devices focused on cardiovascular, diabetes, neurological, and surgical care. The stock has recently traded near $91, corresponding to a market capitalization of roughly $116.8 billion. In its most recent reported quarter, the company achieved its highest annual revenue growth in a decade, with organic growth supported by cardiovascular and diabetes businesses. Analyst activity in recent weeks has included several price target increases ahead of the company’s Q1 fiscal 2027 earnings release scheduled for early September. Pipeline highlights encompass platforms in pulsed-field ablation and other growth areas. Stock movement has aligned with positive sector commentary and pre-earnings positioning, showing resilience relative to some peers amid ongoing macroeconomic influences on healthcare equities.
Trending AI Robots
Tickeron’s Trending AI Robots page curates a selection of high-performing AI trading bots from hundreds available that trade thousands of different tickers. Only those demonstrating strong suitability for prevailing market conditions earn placement in this section. Available bots exhibit varied trading styles, strategies, timeframes, performance metrics, and ticker sets, with historical statistics spanning different risk levels and holding periods. Users can review detailed performance data, win rates, and drawdown profiles to identify options aligned with their objectives. For more information, visit the Trending AI Robots page.
Head-to-Head Comparison
ABT operates with broader diversification across diagnostics and nutrition alongside devices, while MDT maintains a more concentrated focus on implantable and procedural devices. Growth drivers differ, with ABT benefiting from recent acquisitions and new monitoring technologies, and MDT leveraging cardiovascular and diabetes innovation cycles. Recent momentum has favored ABT following guidance raises, whereas MDT has seen analyst support ahead of earnings. Risk factors include regulatory and litigation exposure for both, with ABT carrying a higher valuation multiple that implies greater expectations for sustained execution. Sector exposure remains comparable within healthcare equipment, though market sentiment has responded variably to each company’s specific catalysts and macroeconomic headwinds over recent periods.
Tickeron AI Verdict
Based on observable factors including recent earnings guidance updates, product approvals, and relative valuation positioning, Tickeron’s AI models currently assign a modestly higher probabilistic preference to ABT over MDT in trend consistency and near-term catalyst visibility. MDT retains competitive positioning through analyst upgrades and pipeline momentum. Outcomes remain subject to upcoming earnings and broader market conditions.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABT is a Hold and MDT is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ABT’s FA Score shows that 2 FA rating(s) are green whileMDT’s FA Score has 1 green FA rating(s).
- ABT’s FA Score: 2 green, 3 red.
- MDT’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ABT’s TA Score shows that 3 TA indicator(s) are bullish while MDT’s TA Score has 4 bullish TA indicator(s).
- ABT’s TA Score: 3 bullish, 4 bearish.
- MDT’s TA Score: 4 bullish, 4 bearish.
Price Growth
ABT (@Medical/Nursing Services) experienced а -3.68% price change this week, while MDT (@Medical/Nursing Services) price change was +3.22% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -4.20%. For the same industry, the average monthly price growth was -1.16%, and the average quarterly price growth was -5.15%.
Reported Earning Dates
ABT is expected to report earnings on Oct 21, 2026.
MDT is expected to report earnings on Nov 24, 2026.
Industries' Descriptions
@Medical/Nursing Services (-4.20% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
| ABT | MDT | ABT / MDT | |
| Capitalization | 187B | 120B | 156% |
| EBITDA | 11.7B | 9.81B | 119% |
| Gain YTD | -11.930 | -0.275 | 4,333% |
| P/E Ratio | 35.06 | 23.19 | 151% |
| Revenue | 46.6B | 36.4B | 128% |
| Total Cash | 5.6B | 9.22B | 61% |
| Total Debt | 32.6B | 28B | 116% |
ABT | MDT | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 71 | 36 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 5 Undervalued | 4 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 69 | 71 | |
PRICE GROWTH RATING 1..100 | 49 | 37 | |
P/E GROWTH RATING 1..100 | 7 | 56 | |
SEASONALITY SCORE 1..100 | 75 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
MDT's Valuation (4) in the Medical Specialties industry is in the same range as ABT (5). This means that MDT’s stock grew similarly to ABT’s over the last 12 months.
MDT's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as ABT (100). This means that MDT’s stock grew similarly to ABT’s over the last 12 months.
ABT's SMR Rating (69) in the Medical Specialties industry is in the same range as MDT (71). This means that ABT’s stock grew similarly to MDT’s over the last 12 months.
MDT's Price Growth Rating (37) in the Medical Specialties industry is in the same range as ABT (49). This means that MDT’s stock grew similarly to ABT’s over the last 12 months.
ABT's P/E Growth Rating (7) in the Medical Specialties industry is somewhat better than the same rating for MDT (56). This means that ABT’s stock grew somewhat faster than MDT’s over the last 12 months.
| ABT | MDT | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 52% | 1 day ago 57% |
| Stochastic ODDS (%) | 1 day ago 52% | 1 day ago 53% |
| Momentum ODDS (%) | 1 day ago 46% | 1 day ago 57% |
| MACD ODDS (%) | 1 day ago 58% | 1 day ago 59% |
| TrendWeek ODDS (%) | 1 day ago 53% | 1 day ago 55% |
| TrendMonth ODDS (%) | 1 day ago 52% | 1 day ago 50% |
| Advances ODDS (%) | 13 days ago 55% | 1 day ago 53% |
| Declines ODDS (%) | 1 day ago 54% | 12 days ago 57% |
| BollingerBands ODDS (%) | N/A | 1 day ago 61% |
| Aroon ODDS (%) | 1 day ago 55% | 1 day ago 36% |
Advertisement